Loading clinical trials...

A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients | Clinical Trials | Clareo Health

UNKNOWNPHASE4

A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients

A Randomized Non-inferiority Study of Low-dose and Standard-dose Ticagrelor After Intervention for Acute Coronary Syndrome

NCT04255602•Shanghai Tong Ren Hospital

View on ClinicalTrials.gov

Summary

This study is to evaluate the safety and efficacy of 60mg ticagrelor plus 100mg Aspirin to prevent major adverse cardiovascular and cerebrovascular events in one years after drug-eluting stents implantation for Chinese ACS patients compared with 90mg ticagrelor plus 100mg Aspirin

Eligibility

Age

18 - 90 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Subject must be at least 18 years of age
•2. Patients should have undergone successful percutaneous coronary intervention with drug-eluting stent for acute coronary syndrome
•3. Subject understand the study requirements and the treatment procedures and provided informed consent before the procedure

Exclusion Criteria

•1. Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study
•2. Active bleeding
•3. Known hypersensitivity or contraindication to study medications
•4. Non-cardiac co-morbid conditions are present with life expectancy \<2 year or that may result in protocol non-compliance (per site investigator's medical judgment).
•5. Subjects with Cerebral hemorrhage history
•6. Subjects with stroke history in half a year
•7. subjects with malignant tumor
•8. subjects with whom oral anticoagulants are needed

Locations (8)

Taishan people's hospital

Taishan, Guangdong, China

South East of Shandong hospital

Liaocheng, Shandong, China

zhangshan hospital, Fudan University

Shanghai, Shanghai Municipality, China

shanghai Tongren hospital

Shanghai, Shanghai Municipality, China

Minhang hospital, Fudan University

Shanghai, Shanghai Municipality, China

Songjiang hospital, Shanghai jiaotong university, school of medicine

Shanghai, Shanghai Municipality, China

Ningbo 4th hospital

Xiangshan, Zhejiang, China

Yanzhou branch of affiliated hospital of Jining medical university

Jining, China

Key Dates

Start Date

February 19, 2020

Primary Completion Date

December 31, 2024

Completion Date

December 31, 2024

Last Updated

December 7, 2023

Enrollment

2,120

ESTIMATED participants

Conditions

Acute Coronary SyndromeCoronary Stent Implantation

Interventions

Ticagrelor 60mg

DRUG

Ticagrelor 90mg

DRUG

Contacts

Lei Hou, Doctor

CONTACT

13564868096 Dr_houlei@163.com

Junbo Ge, Doctor

CONTACT

Ge.junbo@zs-hospital.sh.cn

Drug-Coated Balloon Primary PCI in ST-Segment Elevation Myocardial Infarction

NCT07436429

Myocardial Infarction (MI)ST-Elevation Myocardial Infarction+3 more

View study

RECRUITINGNA

Evaluation Through Innovative Examinations of Intestinal Dysbiosis Status in Patients Diagnosed With Cardiovascular Diseases and Evaluation of the Efficacy of Natural and Probiotic Extracts in the Non-pharmacological Approach to Improving Intestinal Dysbiosis Status.

NCT07429227

Acute Coronary Syndromes (ACS)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 7, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients

Inclusion Criteria

Exclusion Criteria

Drug-Coated Balloon Primary PCI in ST-Segment Elevation Myocardial Infarction

Evaluation Through Innovative Examinations of Intestinal Dysbiosis Status in Patients Diagnosed With Cardiovascular Diseases and Evaluation of the Efficacy of Natural and Probiotic Extracts in the Non-pharmacological Approach to Improving Intestinal Dysbiosis Status.

Revascularization Strategies in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) and Severe Coronary Artery Disease

MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study

Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)

A Polypill for Acute Coronary Syndrome